Autism Diagnostics Market Share

North America Market Forecast

Autism diagnostics market in North America region is anticipated to hold largest revenue share of about 30% by the end of 2036. The growth of the market in this region is due to the introduction and quick adoption of several autism medications. It is anticipated that the region's increased ASD research activity is expected to create new growth prospects. The United States has maintained a sizable market share in North America. The prevalence of autism spectrum diseases, rising R&D costs, and an increase in investment volume are the main drivers of market expansion. For example, according to a Centres for Disease Control and Prevention (CDC) update from March 2022, around 1 in 44 children has been diagnosed with autism spectrum disorder (ASD). As a result, the nation's need for treatment for autism spectrum disorders is rising. For example, F. Hoffmann-La Roche Ltd. started a clinical trial research in January 2020 in Toronto, Canada, for individuals with autism using the novel investigational medication Balovaptan. It is anticipated that the study's successful conclusion will stimulate market expansion.

Europe Market Statistics

Europe autism diagnostics market is expected to hold 27% of the revenue share by 2036, owing to the rising R&D activity and a growing public awareness of autism. The growth of the market in this region is because of increased awareness and screening, easier access to assistance, and broader diagnostic criteria. Moreover, it is projected that throughout the projection period, increased product sales will strengthen the market in the area.